Gilead sues US govt for breach of contract over antiviral patents
29-04-2020
World’s scientists working on nearly 80 COVID-19 vaccines
21-04-2020
Canada authorises compulsory licences for COVID-19 shortfalls
27-03-2020
siam.pukkato / Shutterstock.com
Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.
In a time of crisis, access to appropriate pharmaceuticals is of paramount importance. At present there are six UK centres attempting to find an antiviral treatment for the COVID-19 virus.
There are many more other drug interventions being sought around the world to stop the rampage of the virus. The World Health Organization (WHO) lists at least 60 such projects.
Access to patented pharmaceutical subject matter is denied by the ownership of a patent.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
COVID-19, patents, UK, US, Gilead, remdesivir, the world health organization, Wuhan Institute of Technology, Donald Trump, coronavirus, pandemic
